Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis.
Bladder dysfunction
Human T-cell leukemia virus type 1
Human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis
Neurogenic bladder
Urinary symptom score
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
received:
05
02
2020
accepted:
23
06
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Urinary dysfunction is one of the main features of human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, a comprehensive assessment of the severity is difficult because a standardized assessment measure is unavailable. Therefore, this study aimed to develop a novel symptom score for the assessment of urinary dysfunction in HAM/TSP. We interviewed 449 patients with HAM/TSP using four internationally validated questionnaires for assessment of urinary symptoms (27 question items in total): the International Prostate Symptom Score; the International Consultation on Incontinence Questionnaire-Short Form; the Overactive Bladder Symptom Score; and the Nocturia Quality-of-Life questionnaire. We developed a symptom score based on the data of 322 patients who did not use urinary catheters by selecting question items from questionnaires focused on descriptive statistics, correlation analysis, and exploratory factor analysis. The score distribution, reliability, and validity of the developed score were evaluated. First, 16 questions related to quality of life, situations, or subjective assessment were omitted from the 27 questions. Exploratory factor analysis revealed that the remaining 11 questions pertained to three factors: frequent urination, urinary incontinence, and voiding symptoms. Three questions, which had similar questions with larger factor loading, were deleted. Finally, we selected eight question items for inclusion in the novel score. The score distribution exhibited no ceiling or floor effect. The Cronbach's alpha (0.737) demonstrated reliable internal consistency. The new score comprised two subscales with acceptable factorial validity (inter-factor correlation coefficient, 0.322): storage symptoms (frequent urination plus urinary incontinence) and voiding symptoms. The correlation between each item and the subscales suggested acceptable construct validity. We developed a novel score, the HAM/TSP-Bladder Dysfunction Symptom Score, and demonstrated its reliability and validity. The applicability of this score to patients using catheters should be examined in future research.
Sections du résumé
BACKGROUND
Urinary dysfunction is one of the main features of human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, a comprehensive assessment of the severity is difficult because a standardized assessment measure is unavailable. Therefore, this study aimed to develop a novel symptom score for the assessment of urinary dysfunction in HAM/TSP. We interviewed 449 patients with HAM/TSP using four internationally validated questionnaires for assessment of urinary symptoms (27 question items in total): the International Prostate Symptom Score; the International Consultation on Incontinence Questionnaire-Short Form; the Overactive Bladder Symptom Score; and the Nocturia Quality-of-Life questionnaire. We developed a symptom score based on the data of 322 patients who did not use urinary catheters by selecting question items from questionnaires focused on descriptive statistics, correlation analysis, and exploratory factor analysis. The score distribution, reliability, and validity of the developed score were evaluated.
RESULTS
First, 16 questions related to quality of life, situations, or subjective assessment were omitted from the 27 questions. Exploratory factor analysis revealed that the remaining 11 questions pertained to three factors: frequent urination, urinary incontinence, and voiding symptoms. Three questions, which had similar questions with larger factor loading, were deleted. Finally, we selected eight question items for inclusion in the novel score. The score distribution exhibited no ceiling or floor effect. The Cronbach's alpha (0.737) demonstrated reliable internal consistency. The new score comprised two subscales with acceptable factorial validity (inter-factor correlation coefficient, 0.322): storage symptoms (frequent urination plus urinary incontinence) and voiding symptoms. The correlation between each item and the subscales suggested acceptable construct validity.
CONCLUSIONS
We developed a novel score, the HAM/TSP-Bladder Dysfunction Symptom Score, and demonstrated its reliability and validity. The applicability of this score to patients using catheters should be examined in future research.
Identifiants
pubmed: 32620176
doi: 10.1186/s13023-020-01451-3
pii: 10.1186/s13023-020-01451-3
pmc: PMC7333329
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
175Investigateurs
Takeo Nakayama
(T)
Satoshi Kamei
(S)
Jun-Ichi Kira
(JI)
Toshiki Watanabe
(T)
Tatsuo Kohriyama
(T)
Akihiko Okayama
(A)
Atsushi Kawakami
(A)
Kenji Yuzawa
(K)
Masanori Nakagawa
(M)
Tatsufumi Nakamura
(T)
Ryuji Kubota
(R)
Eiji Matsuura
(E)
Koju Kamoi
(K)
Takashi Nakajima
(T)
Hiroyuki Murai
(H)
Kaoru Uchimaru
(K)
Yoshio Tsuboi
(Y)
Yukihiro Namihira
(Y)
Satoshi Ishihara
(S)
Masaaki Niino
(M)
Masahiro Nagai
(M)
Kunihiko Umekita
(K)
Norihiro Takenouchi
(N)
Toshio Matsuzaki
(T)
Youichi Hokezu
(Y)
Hideki Nakamura
(H)
Takuya Matsushita
(T)
Yuji Morio
(Y)
Hisashi Yonezawa
(H)
Takashi Tokashiki
(T)
Keiko Tamaki
(K)
Hirokuni Sakima
(H)
Naoko Yagishita
(N)
Tomohiro Matsuo
(T)
Junji Yamauchi
(J)
Eisuke Inoue
(E)
Ayako Takata
(A)
Natsumi Araya
(N)
Daisuke Hasegawa
(D)
Tomoo Sato
(T)
Yoshihisa Yamano
(Y)
Références
Neurourol Urodyn. 2020 Apr;39(4):1162-1169
pubmed: 32196732
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
Am J Obstet Gynecol. 2002 Jul;187(1):116-26
pubmed: 12114899
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
J Urol. 2014 Aug;192(2):452-7
pubmed: 24518764
Neurology. 1996 Apr;46(4):1016-21
pubmed: 8780082
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
pubmed: 6261256
Urology. 2006 Aug;68(2):318-23
pubmed: 16904444
Neurourol Urodyn. 2004;23(4):322-30
pubmed: 15227649
Res Rep Urol. 2013 Oct 10;5:129-37
pubmed: 24400244
Urology. 2003 Jun;61(6):1118-22
pubmed: 12809877
J Neurol Sci. 2004 Jan 15;217(1):3-6
pubmed: 14675601
Urol Int. 1991;47 Suppl 1:67-8
pubmed: 1949381
J Urol. 2019 Sep;202(3):574-584
pubmed: 30958741
Int Braz J Urol. 2007 Mar-Apr;33(2):238-44; discussion 244-5
pubmed: 17488545
Urol Int. 1991;47 Suppl 1:69-71
pubmed: 1949382
Neuropathology. 2000 Sep;20 Suppl:S65-8
pubmed: 11037191
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
PLoS Negl Trop Dis. 2012;6(6):e1675
pubmed: 22720101
Urology. 2004 Mar;63(3):481-6
pubmed: 15028442
Neurourol Urodyn. 2017 Feb;36(2):449-452
pubmed: 26756420
Orphanet J Rare Dis. 2016 May 25;11(1):69
pubmed: 27225443
Urology. 2007 May;69(5):813-8
pubmed: 17482910
Br J Urol. 1991 Oct;68(4):365-8
pubmed: 1933155
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
J Spinal Disord. 1994 Jun;7(3):255-8
pubmed: 7919650
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208